Patent US2734247A successfully refreshed from Google Patents.
Patent US2102406A successfully refreshed from Google Patents.
US4129720A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Aminoeverninomicin and derivatives thereof
Assignee: Merck Sharp & Dohme LLC
•
Filing: 1977-09-16
•
Granted: 1978-12-12
•
Expires: 1997-09-16
Abstract
Abstract Everninomicin B, C or D may be converted to amino derivatives by reductive means. The amino derivatives may, subsequently, be converted to novel N-acyl, N-alkyl or N,N-dialkyl derivatives. Alternatively, everninomicins B, C or D may be converted to N-acyl-N-hydroxylamino derivatives also by reductive means. The derivatives so-produced and the non-toxic pharmaceutically acceptable cationic salts thereof are novel and are antibacterial agents.
Inventors
- 👤 Ashit K. Ganguly
- 👤 Viyyoor M. Girijavallabhan
- 👤 Olga Sarre
- 👤 Hans Reimann
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-09 03:53
CPC Classifications
C; C07; C07H; C07H19/00; C07H19/01; A; A61; A61P; A61P31/00; A61P31/04
Claims Analysis
Total Claims: 25
Claim 1
Independent Claim
60 words
A compound selected from the group consisting of aminoverninomicin B, aminoeverninomicin C, aminoeverninomicin D, the N-acyl, N-acyl-N-hydroxyl, N-alky, N,N-dialkyl derivatives and non-toxic pharmaceutically acceptable cationic salts thereof wherein said acyl group is derived from a carboxylic acid having 1 to 12 carbon atoms and said alkyl group is a member selected from the group having 1 to 12 carbon atoms.
Claim 2
Dependent Claim
60 words
A compound selected from the group consisting of aminoverninomicin B, aminoeverninomicin C, aminoeverninomicin D, the N-acyl, N-acyl-N-hydroxyl, N-alky, N,N-dialkyl derivatives and non-toxic pharmaceutically acceptable cationic salts thereof wherein said acyl group is derived from a carboxylic acid having 1 to 12 carbon atoms and said alkyl group is a member selected from the group having 1 to 12 carbon atoms.
Claim 3
Dependent Claim
24 words
A compound of claim 1 selected from the group consisting of aminoeverninomicin B, aminoeverninomicin C, aminoeverninomicin D, and non-toxic pharmaceutically acceptable cationic salts thereof.
Claim 4
Dependent Claim
40 words
A compound of claim 1 selected from the group consisting of N-acylaminoeverninomicin B, N-acylaminoeverninomicin C, N-acylaminoeverninomicin D and non-toxic pharmaceutically acceptable cationic salts thereof wherein the acyl group is derived from a carboxylic acid having 1 to 12 carbon atoms.
Claim 5
Dependent Claim
40 words
A compound of claim 1 selected from the group consisting of N-acyl-N-hydroxylaminoeverninomicin B, N-acyl-N-hydroxylaminoeverninomicin C, N-acyl-N-hydroxylaminoeverninomicin D and non-toxic pharmaceutically acceptable cationic salts thereof wherein the acyl group is derived from a carboxylic acid having 1 to 12 carbon atoms.
Claim 6
Dependent Claim
42 words
A compound of claim 1 selected from the group consisting of N-alkylaminoeverninomicin B, N-alkylaminoeverninomicin C and N-alkylaminoeverninomicin D and non-toxic pharmaceutically acceptable cationic salts thereof wherein the alkyl group is a member selected from the group having 1 to 12 carbon atoms.
Claim 7
Dependent Claim
42 words
A compound of claim 1 selected from the group consisting of N,N-dialkylaminoeverninomicin B, N,N-dialkylaminoeverninomicin C and N,N-dialkylaminoeverninomicin D and pharmaceutically acceptable cationic salts thereof wherein each of said alkyl groups are members selected from the group having 1 to 12 carbon atoms.
Claim 8
Dependent Claim
10 words
A compound of claim 2, said compound being aminoeverninomicin B.
Claim 9
Dependent Claim
10 words
A compound of claim 2, said compound being aminoeverninomicin C.
Claim 10
Dependent Claim
10 words
A compound of claim 2, said compound being aminoeverninomicin D.
Claim 11
Dependent Claim
10 words
A compound of claim 3, said compound being N-acetylaminoeverninomicin B.
Claim 12
Dependent Claim
10 words
A compound of claim 3, said compound being N-acetylaminoeverninomicin C.
Claim 13
Dependent Claim
10 words
A compound of claim 3, said compound being N-acetylaminoeverninomicin D.
Claim 14
Dependent Claim
10 words
A compound of claim 4, said compound being N-acetyl-N-hydroxylaminoeverniomicin B.
Claim 15
Dependent Claim
10 words
A compound of claim 4, said compound being N-acetyl-N-hydroxylaminoeverninomicin C.
Claim 16
Dependent Claim
10 words
A compound of claim 4, said compound being N-acetyl-N-hydroxylaminoeverninomicin D.
Claim 17
Dependent Claim
10 words
A compound of claim 5, said compound being N-ethylaminoeverninomicin B.
Claim 18
Dependent Claim
10 words
A compound of claim 5, said compound being N-ethylaminoeverninomicin C.
Claim 19
Dependent Claim
10 words
A compound of claim 5, said compound being N-ethylaminoeverninomicin D.
Claim 20
Dependent Claim
10 words
A compound of claim 6, said compound being N,N-diethylaminoeverninomicin B.
Claim 21
Dependent Claim
10 words
A compound of claim 6, said compound being N,N-diethylaminoeverninomicin C.
Claim 22
Dependent Claim
10 words
A compound of claim 6, said compound being N,N-diethylaminoeverninomicin D.
Claim 23
Dependent Claim
12 words
A non-toxic pharmaceutically acceptable cationic salt of the compound of claim 12.
Claim 24
Dependent Claim
12 words
A compound of claim 22, said compound being N-acetylaminoeverninomicin D sodium salt.
Claim 25
Dependent Claim
12 words
A compound of claim 22, said compound being N-acetylaminoeverninomicin D N-methylglucamine salt.
References Cited (Backward Citations)
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1981-12-11 | 1982-06-12 | 1982-12-12 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1985-12-11 | 1986-06-12 | 1986-12-12 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1989-12-11 | 1990-06-12 | 1990-12-12 | $7700.00 | Window Closed / Lapsed |